<a href="https://www.clickcease.com" rel="nofollow"><img src="https://monitor.clickcease.com/stats/stats.aspx" alt="ClickCease">

Amplifying Precision

High-quality Reagents for Multiplex Respiratory  Point-of-Care (POC) Assays

Multiplex assays for respiratory diseases are particularly challenging due to the potential for cross-reactivity between pathogens and the high sample complexity.  Respiratory specimens often contain various types of cells, mucus, and other components that can interfere with a test and affect assay accuracy.

Meridian offers both highly sensitive and specific reagent solutions for rapid immunoassays and molecular (qPCR and LAMP) techniques to meet your needs.  Read our whitepaper to learn more through real-world case studies!


Point-of-Care (POC) Respiratory Testing

The field of Point-of-care (POC) diagnostics for respiratory diseases has experienced rapid advancements, with the COVID-19 pandemic catalyzing development and widespread adoption of POC respiratory testing. Both paper-based immunodiagnostics and microfluidic molecular devices have received particular attention for the development of POCT assays (Seak Y. et al (2023)). However, POC multiplex assays for respiratory diseases pose considerable challenges, primarily due to the potential for cross-reactivity among different pathogens and the intricate composition of respiratory specimens.

Respiratory tract infections are among the leading causes of illness worldwide, and viral infections caused by influenza, SARS-CoV-2, and respiratory syntactical virus (RSV) are three of the most common, taking up significant healthcare resources and preventive measures to treat and control.  Accordingly, the global respiratory pathogen testing market is expected to grow from US$3.1 billion to US$4.2 billion in just eight years, from 2022 to 2030. With the ongoing evolution of healthcare diagnostics to improve patient care and outcomes, POC testing methods for respiratory diseases are pivotal in facilitating early detection and effective management.

Meridian offers comprehensive solutions to meet your needs with both reagent solutions for rapid immunoassays and molecular tests using either qPCR or LAMP techniques. 

Diagnostic Assay Solutions for Top 3 Viral Infections

Multiplex Rapid Lateral Flow Assays 

Multiplex rapid lateral flow assays for respiratory infections such as the flu, COVID and RSV offer an efficient testing solution. However, due to differences in the viral strains, viral loads, and sample types, balancing high assay sensitivity and specificity can be complex, especially if the viruses share genetic or antigenic similarities, leading to potential cross-reactivity.

Meridian’s monoclonal antibodies for Flu A, Flu B, COVID, and RSV are designed for low cross-reactivity and high sensitivity, ideal for lateral flow rapid multiplex tests for COVID/FLU/RSV.


Molecular Respiratory Assays

Internal control

Multiplex molecular assays are challenging to develop as the assay must detect different targets to the same level of accuracy and sensitivity as a single test. Meridian specializes in enzymes and master mixes for RT-qPCR and RT-LAMP that are designed for fast and sensitive amplification over a wide dynamic range. The key difference in Meridian’s molecular reagents is their optimization for top performance in the presence of PCR inhibitors. By enhancing inhibitor tolerance of the mixes and enzymes, Meridian’s reagents can achieve higher sensitivity and greater assay reliability.

MicrosoftTeams-image (3)-1

Interested to learn more about COVID/Flu/RSV multiplex testing? 

Subscribe to Newsletter


Regus IFC Center 国际财源中心,北京市朝阳区建国门外大街甲8号财源国际中心东塔10层1003室, 中国

座机: 130 51369001
手机: 010-85233176